Journal
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
Volume 24, Issue 4, Pages 683-689Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-14-1217
Keywords
-
Funding
- Intramural Research Program of the National Cancer Institute
- Europe Against Cancer Program of the European Commission (SANCO)
- Deutsche Krebshilfe
- Deutsches Krebsforschungszentrum
- German Federal Ministry of Education and Research
- Danish Cancer Society
- Health Research Fund (FIS) of the Spanish Ministry of Health
- Spanish Regional Government of Andalucia
- Spanish Regional Government of Asturias
- Spanish Regional Government of Basque Country
- Spanish Regional Government of Murcia
- Spanish Regional Government of Navarra
- Catalan Institute of Oncology, Spain
- ISCIII of the Spanish Ministry of Health (RETICC) [DR06/0020]
- Cancer Research UK
- Medical Research Council, United Kingdom
- Greek Ministry of Health
- Stavros Niarchos Foundation
- Hellenic Health Foundation
- Italian Association for Research on Cancer (AIRC)
- Italian National Research Council, Fondazione-Istituto Banco Napoli, Italy
- Associazione Italiana per la Ricerca sul Cancro-AIRC-Milan
- Compagnia di San Paolo
- Dutch Ministry of Public Health, Welfare, and Sports
- World Cancer Research Fund
- Swedish Cancer Society
- Swedish Scientific Council
- Regional Government of Vasterbotten, Sweden
- NordForsk (Centre of excellence programme HELGA), Norway
- French League against Cancer (LNCC), France
- National Institute for Health and Medical Research (INSERM), France
- Mutuelle Generale de l'Education Nationale (MGEN), France
- 3M Co, France
- Gustave Roussy Institute (IGR), France
- General Councils of France
- European Commission's 5th Framework Program [QLK1-2001-00182]
- Health General Directorate of the French Social Affairs and Health Ministry
- European Commission's 7th Framework Program [FP7-HEALTH-2011-282562]
- Intramural Research Program of the Division of Cancer Epidemiology and Genetics
- Division of Cancer Prevention, National Cancer Institute, NIH, DHHS
- Cancer Research UK [16491] Funding Source: researchfish
Ask authors/readers for more resources
Background: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. Methods: A total of 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having (i) moderate [mean fluorescent intensity (MFI) >= 484 and <1,000] or (ii) high seroreactivity (MFI >= 1,000). Associations of moderate and high HPV16 E6 seroreactivity with (i) demographic risk factors; and seropositivity for (ii) other HPV16 proteins (E1, E2, E4, E7, and L1), and (iii) E6 proteins from non-HPV16 types (HPV6, 11, 18, 31, 33, 45, and 52) were evaluated. Results: Thirty-two (0.7%) HPV16 E6 seropositive controls were identified; 17 (0.4%) with moderate and 15 (0.3%) with high seroreactivity. High HPV16 E6 seroreactivity was associated with former smoking [odds ratio (OR), 5.5; 95% confidence interval (CI), 1.2-51.8], and seropositivity againstHPV16 L1 (OR, 4.8; 95% CI, 1.3-15.4); E2 (OR, 7.7; 95% CI, 1.4-29.1); multiple HPV16 proteins (OR, 25.3; 95% CI, 2.6-119.6 for three HPV16 proteins beside E6) and HPV33 E6 (OR, 17.7; 95% CI, 1.9-81.8). No associations were observedwithmoderateHPV16 E6 seroreactivity. Conclusions: High HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not explained by demographic factors. Impact: Some HPV16 E6 seropositive individuals without diagnosedHPV- drivencancer, especiallythosewithseropositivityagainst other HPV16 proteins, may harbor a biologically relevant HPV16 infection. (C) 2015 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available